Revolution Medicines股票讨论区

” 持有量：87
” 前20名的持股量：86.71％
” 季度环比变化**：-9.29%
顶级持股：
$因塞特(INCY.US)$
$百济神州(BGNE.US)$
$阿卡迪亚(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...

$Revolution Medicines(RVMD.US)$ 这家生物技术公司报告了其抗肿瘤药物 RMC-6236 的发现和临床前转化后，周三上涨了10％以上。
根据该公司在出版物中披露的实验药物的消息，RVMD上涨10.6％，收于36.50美元 癌症发现.
Revolution周二在市场收盘前不久披露了该药的消息，使股价当天上涨了3.4％...

$Revolution Medicines(RVMD.US)$
有人刚刚卖出了 25,000 股股票。他们的时机有多好。

$Revolution Medicines(RVMD.US)$
👀👀 突然爆发

$Revolution Medicines(RVMD.US)$ 26.66下车

Focus Financial Downgraded to Market Perform From Outperform at William Blair
William Blair analyst Jeff Schmitt downgraded $Focus Financial Partners(FOCS.US)$ to Market Perform from Outperform after the company reached an agreement to be acquired by Clayton, Dubilier & Rice and Stone Point Capital in an all-cash transaction valued at $53 in cash per share.
Credit Suisse Upgrades Celsius Holdings to Outperform, Raises Price Target to $...